WT5
MCID: WLM018
MIFTS: 64

Wilms Tumor 5 (WT5)

Categories: Cancer diseases, Fetal diseases, Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Wilms Tumor 5

MalaCards integrated aliases for Wilms Tumor 5:

Name: Wilms Tumor 5 58
Wilms Tumor 39 26 13 56 6 44 41
Wilms Tumor Susceptibility-5 58 13
Nephroblastoma 26 74
Wt5 58 76
Hereditary Susceptibility to Wilms Tumor 5 76
Wilms Tumor and Radial Bilateral Aplasia 74
Kidney, Adenomyosarcoma, Embryonal 26
Kidney, Carcinosarcoma, Embryonal 26
Wilms Tumor, Susceptibility to 58
Kidney, Embryonal Mixed Tumor 26
Embryonal Adenosarcoma 26
Renal Cancer, Wilms 26
Wilms Tumor, Type 5 41
Wilms Tumor ; Wtsl 58
Embryonal Nephroma 26
Kidney Wilms Tumor 26
Renal Adenosarcoma 26
Renal Wilms Tumor 26
Kidney, Embryoma 26
Wilms' Tumor 26
Tumor, Wilms 26
Nephroma 26
Wtsl 58

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant
somatic mutation

Miscellaneous:
most cases are sporadic
tumor suppressor gene


HPO:

33

Classifications:



External Ids:

OMIM 58 601583
MedGen 43 C1832099

Summaries for Wilms Tumor 5

MedlinePlus : 44 Wilms tumor is a rare type of kidney cancer. It causes a tumor on one or both kidneys. It usually affects children, but can happen in adults. Having certain genetic conditions or birth defects can increase the risk of getting it. Children that are at risk should be screened for Wilms tumor every three months until they turn eight. Symptoms include a lump in the abdomen, blood in the urine, and a fever for no reason. Tests that examine the kidney and blood are used to find the tumor. Doctors usually diagnose and remove the tumor in surgery. Other treatments include chemotherapy and radiation and biologic therapies. Biologic therapy boosts your body's own ability to fight cancer. NIH: National Cancer Institute

MalaCards based summary : Wilms Tumor 5, also known as wilms tumor, is related to hemihyperplasia, isolated and aniridia 1, and has symptoms including abdominal pain An important gene associated with Wilms Tumor 5 is POU6F2 (POU Class 6 Homeobox 2), and among its related pathways/superpathways are Adhesion and Proteoglycans in cancer. The drugs Vincristine and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include kidney, myeloid and bone, and related phenotypes are nephroblastoma and cardiovascular system

Genetics Home Reference : 26 Wilms tumor is a form of kidney cancer that primarily develops in children. Nearly all cases of Wilms tumor are diagnosed before the age of 10, with two-thirds being found before age 5.

UniProtKB/Swiss-Prot : 76 Hereditary susceptibility to Wilms tumor 5: Pediatric malignancy of kidney and one of the most common solid cancers in childhood.

Wikipedia : 77 Wilms'' tumor, also known as nephroblastoma, is a cancer of the kidneys that typically occurs in... more...

Description from OMIM: 601583

Related Diseases for Wilms Tumor 5

Diseases in the Hereditary Wilms' Tumor family:

Wilms Tumor 1 Wilms Tumor 2
Wilms Tumor 3 Wilms Tumor 4
Wilms Tumor 5 Wilms Tumor 6
Familial Wilms Tumor 2

Diseases related to Wilms Tumor 5 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 433)
# Related Disease Score Top Affiliating Genes
1 hemihyperplasia, isolated 32.3 CDKN1C H19 IGF2 WT1
2 aniridia 1 32.3 IGF2 PAX6 WT1
3 wilms tumor, aniridia, genitourinary anomalies, and mental retardation syndrome 31.8 IGF2 PAX6 WT1
4 hereditary wilms' tumor 31.6 CDKN1C IGF2 PAX6 WT1
5 renal cell carcinoma, nonpapillary 30.1 H19 PAX2 PAX8 WT1
6 hepatoblastoma 30.1 CDKN1C CTNNB1 GPC3 H19 IGF2
7 adrenocortical carcinoma, hereditary 30.0 CDKN1C CTNNB1 H19 IGF2
8 silver-russell syndrome 29.9 CDKN1C H19 IGF2
9 focal segmental glomerulosclerosis 29.9 CDKN1C CTNNB1 PAX2 SYNPO WT1
10 rhabdomyosarcoma 29.5 CCN1 CCN3 H19 IGF2 SLC22A18
11 wilms tumor 1 29.0 CCN1 CCN3 CDKN1C CTNNB1 FZD6 GPC3
12 beckwith-wiedemann syndrome 28.7 CDKN1C GPC3 H19 IGF2 NAP1L4 SLC22A18
13 cervical wilms' tumor 12.4
14 wilms tumor 4 12.4
15 cellular congenital mesoblastic nephroma 12.3
16 wilms tumor predisposition 12.3
17 wilms tumor, aniridia, genitourinary anomalies, mental retardation, and obesity syndrome 12.3
18 adult mesoblastic nephroma 12.2
19 wilms tumor 3 12.2
20 epithelial predominant wilms' tumor 12.2
21 stromal predominant kidney wilms' tumor 12.2
22 global developmental delay, lung cysts, overgrowth, and wilms tumor 12.2
23 mixed cell type kidney wilms' tumor 12.2
24 blastema predominant kidney wilms' tumor 12.2
25 metachronous kidney wilms' tumor 12.2
26 familial wilms tumor 2 12.2
27 classic congenital mesoblastic nephroma 12.1
28 frasier syndrome 11.7
29 mulibrey nanism 11.6
30 malignant cystic nephroma 11.5
31 dicer1-related pleuropulmonary blastoma cancer predisposition syndrome 11.4
32 metanephric adenoma 11.3
33 mosaic variegated aneuploidy syndrome 1 11.3
34 mosaic variegated aneuploidy syndrome 3 11.3
35 wilms tumor and radial bilateral aplasia 11.3
36 mixed epithelial stromal tumour 11.2
37 hyperparathyroidism 2 with jaw tumors 11.1
38 li-fraumeni syndrome 11.1
39 li-fraumeni syndrome 2 11.1
40 rhabdoid tumor predisposition syndrome 1 11.1
41 mosaic variegated aneuploidy syndrome 2 11.1
42 thauvin-robinet-faivre syndrome 11.1
43 simpson-golabi-behmel syndrome 11.1
44 perlman syndrome 11.1
45 myofibromatosis, infantile, 1 11.0
46 infantile myofibromatosis 11.0
47 graham boyle troxell syndrome 11.0
48 aniridia and absent patella 11.0
49 denys-drash syndrome 11.0
50 aniridia 2 11.0

Graphical network of the top 20 diseases related to Wilms Tumor 5:



Diseases related to Wilms Tumor 5

Symptoms & Phenotypes for Wilms Tumor 5

Human phenotypes related to Wilms Tumor 5:

33
# Description HPO Frequency HPO Source Accession
1 nephroblastoma 33 HP:0002667

Symptoms via clinical synopsis from OMIM:

58
Genitourinary Kidneys:
nephroblastoma (wilms tumor)

Neoplasia:
nephroblastoma (wilms tumor)

Clinical features from OMIM:

601583

UMLS symptoms related to Wilms Tumor 5:


abdominal pain

MGI Mouse Phenotypes related to Wilms Tumor 5:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.97 CCN1 CCN3 CTNNB1 GPC3 IGF2 PAX2
2 embryo MP:0005380 9.96 CCN1 CTNNB1 FZD6 GPC3 IGF2 PAX2
3 mortality/aging MP:0010768 9.73 CCN1 CCN3 CTNNB1 FZD6 GPC3 IGF2
4 limbs/digits/tail MP:0005371 9.63 CCN3 CTNNB1 FZD6 GPC3 IGF2 PAX8
5 renal/urinary system MP:0005367 9.28 CCN3 CTNNB1 GPC3 IGF2 PAX2 PAX6

Drugs & Therapeutics for Wilms Tumor 5

Drugs for Wilms Tumor 5 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 308)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 6055-19-2, 50-18-0 2907
3
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
4
Dactinomycin Approved, Investigational Phase 4,Phase 3,Phase 2 50-76-0 457193 2019
5
Epirubicin Approved Phase 4,Phase 2 56420-45-2 41867
6
Oxytetracycline Approved, Investigational, Vet_approved Phase 4 79-57-2 54715139 5280972
7
Itraconazole Approved, Investigational Phase 4,Phase 3,Not Applicable 84625-61-6 55283
8
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
9
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
10
Pirarubicin Investigational Phase 4 72496-41-4
11 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
12 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
14 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
17 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
18 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
20 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
22 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
24 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
29 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30
Hydroxyitraconazole Phase 4,Phase 3,Not Applicable
31
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
32
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 38904 10339178 498142
33
Decitabine Approved, Investigational Phase 2, Phase 3,Phase 1 2353-33-5 451668
34
Sargramostim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 123774-72-1, 83869-56-1
35
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
36
Morphine Approved, Investigational Phase 3 57-27-2 5288826
37
Idarubicin Approved Phase 2, Phase 3,Phase 3 58957-92-9 42890
38
Cytarabine Approved, Experimental, Investigational Phase 2, Phase 3,Phase 3,Phase 1 147-94-4, 65-46-3 6253
39
Daunorubicin Approved Phase 3,Phase 2,Phase 1 20830-81-3 30323
40
Sulfamethoxazole Approved Phase 3 723-46-6 5329
41
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
42
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1 75607-67-9, 21679-14-1 30751
43
Cyproheptadine Approved Phase 3 129-03-3 2913
44
Histamine Approved, Investigational Phase 3,Phase 1,Phase 2 51-45-6 774
45
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 55-98-1 2478
46
Methotrexate Approved Phase 2, Phase 3 1959-05-2, 59-05-2 126941
47
Tacrolimus Approved, Investigational Phase 2, Phase 3 104987-11-3 445643 439492 6473866
48
Mycophenolic acid Approved Phase 3 24280-93-1 446541
49
Captopril Approved Phase 3 62571-86-2 44093
50
Palivizumab Approved, Investigational Phase 3 188039-54-5

Interventional clinical trials:

(show top 50) (show all 265)
# Name Status NCT ID Phase Drugs
1 Combination Therapy of Anthracyclines for Children With Nephroblastoma Not yet recruiting NCT03892330 Phase 4 Vincristine;Oxytetracycline/ Cyclophosphamide;Liposomal doxorubicin;Doxorubicin;Pharmorubicin;Pirarubicin
2 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
3 Chemotherapy Plus Surgery in Treating Children at Risk of or With Stage I Wilms' Tumor Unknown status NCT00003804 Phase 3 vincristine sulfate
4 Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor Unknown status NCT00047138 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
5 Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Unknown status NCT01809392 Phase 2, Phase 3 decitabine
6 Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Unknown status NCT01987596 Phase 3
7 Safety and Efficacy Study of Microtransplantation to Treat Elderly Acute Myeloid Leukemia Unknown status NCT02171117 Phase 3
8 Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor Completed NCT00379340 Phase 3 doxorubicin hydrochloride;liposomal vincristine sulfate;cyclophosphamide;etoposide
9 Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor Completed NCT00352534 Phase 3 vincristine sulfate;doxorubicin hydrochloride
10 Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Completed NCT00945009 Phase 3 Doxorubicin Hydrochloride;Vincristine Sulfate
11 WT1 for the Detection of Minimal Residual Disease Completed NCT00179829 Phase 2, Phase 3
12 Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors Completed NCT00002610 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
13 Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer Completed NCT00002611 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
14 Clinical Trial for Patients With a Stage IV Childhood Renal Tumor, Comparing Upfront Vincristine, Actinomycin-D and Doxorubicin (Standard Arm) With Upfront Vincristine, Carboplatin and Etoposide (Experimental Arm) Not yet recruiting NCT03669783 Phase 3 treatment Vincristin;treatment Actinomycin-D;treatment Doxorubicin;treatment Carboplatin;Etoposide
15 Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer Completed NCT00369564 Phase 3 glutamic acid
16 Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML) Completed NCT00909168 Phase 2, Phase 3 FLAIMy - Fluda, Ida, Ara-C, Mylotarg
17 Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk Completed NCT00860639 Phase 3 gemtuzumab ozogamycin
18 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
19 Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4 Recruiting NCT02473146 Phase 2, Phase 3 Gemtuzumab ozogamicin (GO)
20 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
21 Family-mismatched/Haploidentical Donors Versus Matched Unrelated Donors Active, not recruiting NCT01751997 Phase 2, Phase 3 Transplants from 8/8-matched Unrelated donors;Transplants from family-mismatched/haploidentical donors
22 HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk Completed NCT02461121 Phase 3 cyclosporine A;Mycophenolate mofetil;Ara-C;fludarabine;anti-lymphocyte globulin;cyclophosphamide
23 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
24 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
25 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
26 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
27 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
28 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
29 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
30 A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old Completed NCT00927498 Phase 3 conventional chemotherapy (AraC + Daunorubicin),;Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),
31 Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia Unknown status NCT01513109 Phase 1, Phase 2
32 WT1 Peptid Vaccination in Carcinomas Unknown status NCT00153608 Phase 2
33 Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplant in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney Unknown status NCT00025103 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;melphalan;vincristine sulfate
34 WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML) Unknown status NCT00153582 Phase 2
35 Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma Unknown status NCT00965224 Phase 2
36 Dendritic Cell Vaccination for Patients With Solid Tumors Unknown status NCT01291420 Phase 1, Phase 2
37 Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors Unknown status NCT00179816 Phase 1, Phase 2 High-Dose Chemotherapy with Tandem PBSC Rescue.
38 Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT Unknown status NCT01956630 Phase 1, Phase 2
39 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
40 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Unknown status NCT00036712 Phase 2
41 A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients Completed NCT02550535 Phase 1, Phase 2
42 Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy Completed NCT00433745 Phase 2 WT1 Peptide Vaccine
43 A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor Completed NCT00187031 Phase 2 Topotecan, Filgrastim (G-CSF), Pegfilgrastim
44 WT-1 Analog Peptide Vaccine in Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) Completed NCT01266083 Phase 2
45 WT-1 Analog Peptide Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy Completed NCT01265433 Phase 2
46 WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study Completed NCT01621724 Phase 1, Phase 2
47 Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134 Active, not recruiting NCT01890980 Phase 2
48 Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors Recruiting NCT02581384 Phase 1, Phase 2
49 WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation Completed NCT01334060 Phase 2
50 Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood Completed NCT00923910 Phase 1, Phase 2 WT1 Peptide-Pulsed Dendritic Cells;Donor Lymphocytes;IL-4;KLH;WT1 Peptides;Endotoxin;Diphenhydramine;Acetaminophen

Search NIH Clinical Center for Wilms Tumor 5

Genetic Tests for Wilms Tumor 5

Anatomical Context for Wilms Tumor 5

MalaCards organs/tissues related to Wilms Tumor 5:

42
Kidney, Myeloid, Bone, T Cells, Bone Marrow, Testes, Brain

Publications for Wilms Tumor 5

Articles related to Wilms Tumor 5:

(show top 50) (show all 3044)
# Title Authors Year
1
Lessons from a patient with cardiac arrest due to massive pulmonary embolism as the initial presentation of Wilms tumor: a case report and literature review. ( 30704433 )
2019
2
Impact of cyclophosphamide and etoposide on outcome of clear cell sarcoma of the kidney treated on the National Wilms Tumor Study-5 (NWTS-5). ( 30255545 )
2019
3
The Rare Association of Cleft Lip and/or Palate and Wilms Tumor. ( 30712371 )
2019
4
What should we tackle next in acute myeloid leukemia? Wilms tumor gene 1 vaccine therapy would be a promising and versatile strategy for acute myeloid leukemia. ( 30882253 )
2019
5
Measurable residual disease monitoring using Wilms tumor gene 1 expression in childhood acute myeloid leukemia based on child-specific reference values. ( 30900388 )
2019
6
Physiological functions of Wilms' tumor 1-associating protein and its role in tumourigenesis. ( 30756410 )
2019
7
The cell tube block technique and an immunohistochemistry panel including Wilms tumor 1 to assist in diagnosing cavitary effusions in dogs and cats. ( 30865320 )
2019
8
Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer. ( 30306202 )
2019
9
Wilms Tumor-1 (WT1) rs16754 Polymorphism ( 30520285 )
2019
10
Inhibition of Heme Oxygenase-1 Activity Enhances Wilms Tumor-1-Specific T-Cell Responses in Cancer Immunotherapy. ( 30678050 )
2019
11
Wilms tumor 1 expression: addressing the 'elephant' in MDS. ( 30714447 )
2019
12
The coexistence of a Wilms' tumor and renal cell carcinoma in children: a case report and review of the literature. ( 30774381 )
2019
13
Synchronous Bilateral Wilms Tumor: Five-Year Single-Center Experience with Assessment of Quality of Life. ( 30686888 )
2019
14
TRIM28 haploinsufficiency predisposes to Wilms tumor. ( 30694527 )
2019
15
Determining the optimal cutoff point for lymph node density and its impact on overall survival in children with Wilms' tumor. ( 30697068 )
2019
16
Educational Case: Wilms Tumor (Nephroblastoma). ( 30733996 )
2019
17
Botryoid Wilms Tumor: A Rare Diagnosis With An Atypical Presentation. ( 30735745 )
2019
18
The Wilms' tumor suppressor gene regulates pancreas homeostasis and repair. ( 30763305 )
2019
19
Agreement between clinicoradiological signs at diagnosis and radiohistological analysis after neoadjuvant chemotherapy of suspected Wilms tumor rupture: Consequences on therapeutic choices. ( 30773805 )
2019
20
MiR-155-5p affects Wilms' tumor cell proliferation and apoptosis via targeting CREB1. ( 30779069 )
2019
21
Intracardiac Extension of Wilms Tumor: A Case of a 2.5-Year-Old Girl Presenting with Upper Venous Congestion Caused by Tumor Growth into the Right Cardiac Ventricle. ( 30792643 )
2019
22
miR-483-5p Targets MKNK1 to Suppress Wilms' Tumor Cell Proliferation and Apoptosis In Vitro and In Vivo. ( 30798328 )
2019
23
The Natural History of Wilms Tumor - A Case Comparison of Two Different Tumors. ( 30807774 )
2019
24
Salidroside inhibits the growth, migration and invasion of Wilms' tumor cells through down-regulation of miR-891b. ( 30822424 )
2019
25
A1CF-Axin2 signal axis regulates apoptosis and migration in Wilms tumor-derived cells through Wnt/β-catenin pathway. ( 30825095 )
2019
26
Curcumin suppresses wilms' tumor metastasis by inhibiting RECK methylation. ( 30841433 )
2019
27
Association of KRAS and NRAS gene polymorphisms with Wilms tumor risk: a four-center case-control study. ( 30860980 )
2019
28
miR-140-5p alleviates the aggressive progression of Wilms' tumor through directly targeting TGFBR1 gene. ( 30863174 )
2019
29
PAI-1 and protein C as early markers of veno-occlusive disease in patients treated for Wilms tumor. ( 30865371 )
2019
30
Clinical Diagnosis Value of Chest X-Ray and Ultrasound in Recurrence in Patients With Favorable-Histology Wilms Tumor. ( 30875279 )
2019
31
FXR1 expression domain in Wilms tumor. ( 30894247 )
2019
32
Rare clinical condition during Wilms' tumor treatment: Testicular metastasis. ( 30916857 )
2019
33
Autophagy related markers (Beclin-1 and ATG4B) are strongly expressed in Wilms' tumor and correlate with favorable histology. ( 29989143 )
2019
34
Continuing barriers to care of Wilms tumor in a low-income country. ( 30152039 )
2019
35
Outcome of Wilms tumor patients with bone metastasis enrolled on National Wilms Tumor Studies 1-5: A report from the Children's Oncology Group. ( 30160355 )
2019
36
Paternally inherited WT1 mutation plus uniparental disomy of 11p may be an essential mechanism for development of WT1-mutated familial Wilms tumor. ( 30221469 )
2019
37
Fetal programming and Wilms tumor. ( 30255546 )
2019
38
Maintenance chemotherapy to reduce the risk of a metachronous Wilms tumor in children with bilateral nephroblastomatosis. ( 30334607 )
2019
39
Loss or oncogenic mutation of DROSHA impairs kidney development and function, but is not sufficient for Wilms tumor formation. ( 30367465 )
2019
40
The effect of preoperative chemotherapy on histological subtyping and staging of Wilms tumors: The United Kingdom Children's Cancer Study Group (UKCCSG) Wilms tumor trial 3 (UKW3) experience. ( 30408319 )
2019
41
Botryoid Wilms tumor: a non-existent "entity" causing diagnostic and staging difficulties. ( 30515564 )
2019
42
Retraction of: Long Noncoding RNA SOX2OT Accelerates the Carcinogenesis of Wilms' Tumor Through ceRNA Through miR-363/FOXP4 Axis, by Ma L, Sun X, Kuai W, Hu J, Yuan Y, Feng W, and Lu X. DNA Cell Biol [Epub ahead of print]; DOI: 10.1089/dna.2018.4420, 2018. ( 30576227 )
2019
43
Pharmacotherapeutic Management of Wilms Tumor: An Update. ( 30604241 )
2019
44
TP53 rs1042522 C>G polymorphism and Wilms tumor susceptibility in Chinese children: a four-center case-control study. ( 30610160 )
2019
45
A Case of Primary Paratesticular Wilms Tumor in an Undescended Testis. ( 30610907 )
2019
46
Altered VEGF Splicing Isoform Balance in Tumor Endothelium Involves Activation of Splicing Factors Srpk1 and Srsf1 by the Wilms' Tumor Suppressor Wt1. ( 30641926 )
2019
47
Immunohistochemical analysis of cyclin A expression in Wilms tumor. ( 30648000 )
2019
48
The Wilms tumor gene (WT1) (+ / - KTS) isoforms regulate steroidogenesis by modulating the PI3K/AKT and ERK1/2 pathways in bovine granulosa cells. ( 30649196 )
2019
49
Weighted gene co‑expression network analysis for identifying hub genes in association with prognosis in Wilms tumor. ( 30664180 )
2019
50
Correlations between Histological and Array Comparative Genomic Hybridization Characterizations of Wilms Tumor. ( 30671724 )
2019

Variations for Wilms Tumor 5

UniProtKB/Swiss-Prot genetic disease variations for Wilms Tumor 5:

76
# Symbol AA change Variation ID SNP ID
1 POU6F2 p.Gln192His VAR_022419

ClinVar genetic disease variations for Wilms Tumor 5:

6 (show top 50) (show all 199)
# Gene Variation Type Significance SNP ID Assembly Location
1 SMAD4 NM_005359.5(SMAD4): c.875C> T (p.Pro292Leu) single nucleotide variant Uncertain significance rs786201404 GRCh38 Chromosome 18, 51058427: 51058427
2 SMAD4 NM_005359.5(SMAD4): c.875C> T (p.Pro292Leu) single nucleotide variant Uncertain significance rs786201404 GRCh37 Chromosome 18, 48584797: 48584797
3 WT1 NM_024426.5(WT1): c.123G> C (p.Pro41=) single nucleotide variant Benign/Likely benign rs555140661 GRCh37 Chromosome 11, 32456784: 32456784
4 WT1 NM_024426.5(WT1): c.123G> C (p.Pro41=) single nucleotide variant Benign/Likely benign rs555140661 GRCh38 Chromosome 11, 32435238: 32435238
5 WT1 NM_024426.5(WT1): c.345C> T (p.Pro115=) single nucleotide variant Benign rs1799925 GRCh37 Chromosome 11, 32456562: 32456562
6 WT1 NM_024426.5(WT1): c.345C> T (p.Pro115=) single nucleotide variant Benign rs1799925 GRCh38 Chromosome 11, 32435016: 32435016
7 WT1 NM_024426.5(WT1): c.1122A> G (p.Arg374=) single nucleotide variant Benign rs16754 GRCh37 Chromosome 11, 32417945: 32417945
8 WT1 NM_024426.5(WT1): c.1122A> G (p.Arg374=) single nucleotide variant Benign rs16754 GRCh38 Chromosome 11, 32396399: 32396399
9 POU6F2 NM_007252.3(POU6F2): c.573G> T (p.Gln191His) single nucleotide variant Pathogenic rs121918261 GRCh37 Chromosome 7, 39379302: 39379302
10 POU6F2 NM_007252.3(POU6F2): c.573G> T (p.Gln191His) single nucleotide variant Pathogenic rs121918261 GRCh38 Chromosome 7, 39339703: 39339703
11 POU6F2 POU6F2, C-G, EXON 1C, 5-PRIME UTR single nucleotide variant Pathogenic
12 VHL NM_000551.3(VHL): c.241C> T (p.Pro81Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs104893829 GRCh37 Chromosome 3, 10183772: 10183772
13 VHL NM_000551.3(VHL): c.241C> T (p.Pro81Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs104893829 GRCh38 Chromosome 3, 10142088: 10142088
14 CTNNB1 NM_001904.3(CTNNB1): c.133_135delTCT (p.Ser45del) deletion Pathogenic rs587776850 GRCh38 Chromosome 3, 41224645: 41224647
15 CTNNB1 NM_001904.3(CTNNB1): c.133_135delTCT (p.Ser45del) deletion Pathogenic rs587776850 GRCh37 Chromosome 3, 41266136: 41266138
16 CTNNB1 NM_001904.3(CTNNB1): c.134C> T (p.Ser45Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913409 GRCh37 Chromosome 3, 41266137: 41266137
17 CTNNB1 NM_001904.3(CTNNB1): c.134C> T (p.Ser45Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913409 GRCh38 Chromosome 3, 41224646: 41224646
18 MED12 NM_005120.2(MED12): c.131G> A (p.Gly44Asp) single nucleotide variant other rs199469672 GRCh37 Chromosome X, 70339254: 70339254
19 MED12 NM_005120.2(MED12): c.131G> A (p.Gly44Asp) single nucleotide variant other rs199469672 GRCh38 Chromosome X, 71119404: 71119404
20 WT1 NM_024426.5(WT1): c.1114-9T> C single nucleotide variant Benign/Likely benign rs5030274 GRCh38 Chromosome 11, 32396416: 32396416
21 WT1 NM_024426.5(WT1): c.1114-9T> C single nucleotide variant Benign/Likely benign rs5030274 GRCh37 Chromosome 11, 32417962: 32417962
22 WT1 NM_024426.5(WT1): c.375C> T (p.Gly125=) single nucleotide variant Conflicting interpretations of pathogenicity rs776209354 GRCh38 Chromosome 11, 32434986: 32434986
23 WT1 NM_024426.5(WT1): c.375C> T (p.Gly125=) single nucleotide variant Conflicting interpretations of pathogenicity rs776209354 GRCh37 Chromosome 11, 32456532: 32456532
24 WT1 NM_024426.5(WT1): c.309C> A (p.Gly103=) single nucleotide variant Benign/Likely benign rs547333427 GRCh38 Chromosome 11, 32435052: 32435052
25 WT1 NM_024426.5(WT1): c.309C> A (p.Gly103=) single nucleotide variant Benign/Likely benign rs547333427 GRCh37 Chromosome 11, 32456598: 32456598
26 WT1 NM_024426.5(WT1): c.216G> T (p.Gln72His) single nucleotide variant Benign/Likely benign rs5030135 GRCh38 Chromosome 11, 32435145: 32435145
27 WT1 NM_024426.5(WT1): c.216G> T (p.Gln72His) single nucleotide variant Benign/Likely benign rs5030135 GRCh37 Chromosome 11, 32456691: 32456691
28 WT1 NM_024426.5(WT1): c.181C> A (p.Arg61=) single nucleotide variant Benign/Likely benign rs2234581 GRCh38 Chromosome 11, 32435180: 32435180
29 WT1 NM_024426.5(WT1): c.181C> A (p.Arg61=) single nucleotide variant Benign/Likely benign rs2234581 GRCh37 Chromosome 11, 32456726: 32456726
30 WT1 NM_024426.5(WT1): c.83G> A (p.Gly28Glu) single nucleotide variant Uncertain significance rs751641518 GRCh38 Chromosome 11, 32435278: 32435278
31 WT1 NM_024426.5(WT1): c.83G> A (p.Gly28Glu) single nucleotide variant Uncertain significance rs751641518 GRCh37 Chromosome 11, 32456824: 32456824
32 WT1 NM_024426.5(WT1): c.1074A> G (p.Gln358=) single nucleotide variant Benign/Likely benign rs2234590 GRCh37 Chromosome 11, 32421533: 32421533
33 WT1 NM_024426.5(WT1): c.1074A> G (p.Gln358=) single nucleotide variant Benign/Likely benign rs2234590 GRCh38 Chromosome 11, 32399987: 32399987
34 WT1 NM_024426.5(WT1): c.696C> T (p.Ser232=) single nucleotide variant Benign/Likely benign rs9332974 GRCh38 Chromosome 11, 32428585: 32428585
35 WT1 NM_024426.5(WT1): c.696C> T (p.Ser232=) single nucleotide variant Benign/Likely benign rs9332974 GRCh37 Chromosome 11, 32450131: 32450131
36 WT1 NM_024426.5(WT1): c.609C> T (p.Asn203=) single nucleotide variant Benign/Likely benign rs2234583 GRCh37 Chromosome 11, 32456298: 32456298
37 WT1 NM_024426.5(WT1): c.609C> T (p.Asn203=) single nucleotide variant Benign/Likely benign rs2234583 GRCh38 Chromosome 11, 32434752: 32434752
38 WT1 NM_024426.5(WT1): c.513C> A (p.Gly171=) single nucleotide variant Benign/Likely benign rs536728682 GRCh38 Chromosome 11, 32434848: 32434848
39 WT1 NM_024426.5(WT1): c.513C> A (p.Gly171=) single nucleotide variant Benign/Likely benign rs536728682 GRCh37 Chromosome 11, 32456394: 32456394
40 WT1 NM_024426.5(WT1): c.381C> G (p.Pro127=) single nucleotide variant Conflicting interpretations of pathogenicity rs771681406 GRCh38 Chromosome 11, 32434980: 32434980
41 WT1 NM_024426.5(WT1): c.381C> G (p.Pro127=) single nucleotide variant Conflicting interpretations of pathogenicity rs771681406 GRCh37 Chromosome 11, 32456526: 32456526
42 WT1 NM_024426.5(WT1): c.213G> T (p.Pro71=) single nucleotide variant Benign rs2234582 GRCh37 Chromosome 11, 32456694: 32456694
43 WT1 NM_024426.5(WT1): c.213G> T (p.Pro71=) single nucleotide variant Benign rs2234582 GRCh38 Chromosome 11, 32435148: 32435148
44 WT1 NM_024426.5(WT1): c.*1132A> T single nucleotide variant Likely benign rs5030328 GRCh38 Chromosome 11, 32387926: 32387926
45 WT1 NM_024426.5(WT1): c.*1132A> T single nucleotide variant Likely benign rs5030328 GRCh37 Chromosome 11, 32409472: 32409472
46 WT1 NM_024426.5(WT1): c.*1098C> T single nucleotide variant Likely benign rs5030327 GRCh38 Chromosome 11, 32387960: 32387960
47 WT1 NM_024426.5(WT1): c.*1098C> T single nucleotide variant Likely benign rs5030327 GRCh37 Chromosome 11, 32409506: 32409506
48 WT1 NM_024426.5(WT1): c.*1058G> T single nucleotide variant Uncertain significance rs886048211 GRCh38 Chromosome 11, 32388000: 32388000
49 WT1 NM_024426.5(WT1): c.*1058G> T single nucleotide variant Uncertain significance rs886048211 GRCh37 Chromosome 11, 32409546: 32409546
50 WT1 NM_024426.5(WT1): c.*1053_*1054dup duplication Uncertain significance rs58549495 GRCh38 Chromosome 11, 32388004: 32388005

Expression for Wilms Tumor 5

Search GEO for disease gene expression data for Wilms Tumor 5.

Pathways for Wilms Tumor 5

Pathways related to Wilms Tumor 5 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.59 CCN1 CCN3 CTNNB1
2 11.56 CTNNB1 FZD6 GPC3 IGF2
3 11.48 CTNNB1 FZD6 IGF2
4 10.89 CDKN1C CTNNB1 PAX2 SYNPO WT1
5 10.36 PAX2 PAX8

GO Terms for Wilms Tumor 5

Biological processes related to Wilms Tumor 5 according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.97 CCN1 CTNNB1 IGF2 PAX2 PAX6 PAX8
2 central nervous system development GO:0007417 9.86 PAX6 PAX8 POU6F2
3 animal organ morphogenesis GO:0009887 9.85 GPC3 IGF2 PAX6
4 anatomical structure morphogenesis GO:0009653 9.85 CCN1 GPC3 PAX8
5 inner ear morphogenesis GO:0042472 9.81 FZD6 PAX2 PAX8
6 negative regulation of epithelial cell proliferation GO:0050680 9.8 CDKN1C GPC3 PAX6
7 transcription by RNA polymerase II GO:0006366 9.73 PAX2 PAX6 POU6F2
8 male genitalia development GO:0030539 9.67 CTNNB1 WT1
9 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.67 PAX2 PAX8
10 urogenital system development GO:0001655 9.67 PAX2 PAX8
11 anterior/posterior axis specification GO:0009948 9.66 CTNNB1 GPC3
12 mesonephros development GO:0001823 9.66 PAX2 PAX8
13 mesenchymal to epithelial transition GO:0060231 9.65 PAX2 WT1
14 transcription, DNA-templated GO:0006351 9.65 PAX2 PAX8
15 cellular response to gonadotropin stimulus GO:0071371 9.65 PAX8 WT1
16 dorsal/ventral axis specification GO:0009950 9.64 CTNNB1 PAX6
17 metanephric mesenchyme development GO:0072075 9.64 PAX2 WT1
18 mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0003337 9.62 PAX2 PAX8
19 embryonic placenta morphogenesis GO:0060669 9.61 CDKN1C IGF2
20 pronephros development GO:0048793 9.6 PAX2 PAX8
21 regulation of metanephric nephron tubule epithelial cell differentiation GO:0072307 9.59 PAX2 PAX8
22 metanephric S-shaped body morphogenesis GO:0072284 9.58 PAX8 WT1
23 positive regulation of epithelial cell differentiation GO:0030858 9.58 CTNNB1 PAX6
24 camera-type eye development GO:0043010 9.56 CDKN1C PAX2 PAX6 WT1
25 metanephric distal convoluted tubule development GO:0072221 9.55 PAX2 PAX8
26 kidney development GO:0001822 9.55 CDKN1C CTNNB1 GPC3 PAX8 WT1
27 metanephric nephron tubule formation GO:0072289 9.54 PAX2 PAX8
28 positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0072108 9.52 PAX2 PAX8
29 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.51 PAX2 PAX8
30 cell fate determination GO:0001709 9.5 CTNNB1 PAX2 PAX6
31 negative regulation of apoptotic process involved in metanephric collecting duct development GO:1900215 9.49 PAX2 PAX8
32 negative regulation of apoptotic process involved in metanephric nephron tubule development GO:1900218 9.48 PAX2 PAX8
33 negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis GO:0072305 9.46 PAX2 PAX8
34 positive regulation of metanephric DCT cell differentiation GO:2000594 9.43 PAX2 PAX8
35 pronephric field specification GO:0039003 9.4 PAX2 PAX8
36 metanephric epithelium development GO:0072207 9.13 PAX2 PAX8 WT1
37 branching involved in ureteric bud morphogenesis GO:0001658 9.02 CTNNB1 GPC3 PAX2 PAX8 WT1
38 regulation of transcription, DNA-templated GO:0006355 10.21 CTNNB1 IGF2 PAX2 PAX6 PAX8 POU6F2
39 multicellular organism development GO:0007275 10.17 FZD6 IGF2 PAX2 PAX6 PAX8 POU6F2
40 positive regulation of transcription, DNA-templated GO:0045893 10.04 CDKN1C CTNNB1 PAX2 PAX6 PAX8 WT1

Molecular functions related to Wilms Tumor 5 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity GO:0003700 9.43 CTNNB1 PAX6 PAX8 POU6F2 PRDM2 WT1
2 integrin binding GO:0005178 9.33 CCN1 CCN3 IGF2
3 transcription regulatory region DNA binding GO:0044212 8.92 PAX2 PAX6 PAX8 WT1

Sources for Wilms Tumor 5

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....